http://www.pathway2curis.com/pdf/CurisPresentation06August09.pdf

See link above to download august 2006 corp presentation

Curis, Inc. Announces New Cancer Programs, Formation of China-Based Subsidiary; China Location to Initially Focus on New Proprietary Small Molecule Cancer Programs

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 12, 2006--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, today announced that it has formed a wholly foreign-owned enterprise form of subsidiary in Shanghai, China. Earlier in 2006, Curis had initiated development work on several proprietary cancer programs through its relationship with Shanghai ChemPartner, a leading Chinese medicinal chemistry contract researcher. With the establishment of Curis Pharmaceuticals (Shanghai) Co., Ltd. ("Curis Shanghai"), Curis will seek to leverage China's mature, cost-efficient medicinal chemistry industry as a means of broadening Curis' pipeline of drug programs.

Curis joins a growing number of U.S. pharmaceutical and biotechnology companies that have established collaborative relationships in China. Many of the largest companies in the pharmaceutical industry have established a presence in China, either through subsidiaries or through service contracts with Chinese medicinal chemistry providers, tapping into the country's extensive intellectual capital and advantageous economic environment. Curis will combine a subsidiary presence with expansion of its current contractual agreement with Shanghai ChemPartner.

Daniel R. Passeri, President and CEO of Curis, Inc., stated, "Our increased development efforts in China, as typified by the formation of Curis Shanghai, should prove to be an important asset for Curis. We expect it to be a gateway to achieving new levels of speed and efficiency in our drug development programs. We believe that by capitalizing on the recognized high level of medicinal chemistry that exists in China and the country's favorable economic conditions, we have the potential to advance multiple programs much more effectively by reducing costs, increasing productivity, and exploiting the time difference between our two operations. We believe that the collective impact of these advantages will enable us to develop drug candidates at a much more rapid pace than would otherwise be possible. For example, we initiated new cancer programs earlier in 2006, and through our collaboration in China we believe we have already generated meaningful preclinical data on several programs and expect to soon advance several programs into xenograft preclinical cancer models. Operations in China are also expected to share and support our new focus on later-stage preclinical drug programs and our de-emphasis of discovery research efforts. As we announced in June, we believe that targeting later-stage preclinical drug development programs will mitigate risk, maximize our core competencies and allow for a more rapid decision making process with respect to our programs, providing for a potentially more robust and developed pipeline."

About Curis' New Cancer Programs

In recent months, Curis has been developing several classes of new proprietary small molecule drug candidates, each of which is designed to target multiple distinct molecular pathways. Curis believes that some of the most effective currently marketed therapies are those that attack cancer from multiple directions simultaneously. In addition, Curis believes that multi-targeting has an additional advantage because such therapies may help reduce the emergence of drug resistant populations of cells within the tumor. Unlike other recent multi-targeted inhibitors, which target multiple closely related tyrosine kinase receptors, Curis' drugs are being developed as single molecules that target multiple distinct molecular pathways that Curis believes will provide anti-tumor activity across a broad range of hematologic (i.e., blood) and solid tumor cancers.

Curis anticipates that its multi-targeted pathway inhibitors may improve efficacy, prevent the emergence of drug resistance, and/or decrease the dose-limiting toxicities, possibly by virtue of the ability to reduce dosing frequency or amount. Further, Curis believes that these new inhibitors may represent a new paradigm in rational multi-pathway targeting drug development.

These new drug programs are currently in mid-preclinical testing. The Company will seek to progress several classes of compounds simultaneously through preclinical development. Factors to be considered in prioritizing potential drug candidates include efficacy, pharmacology, patient needs, path to regulatory approval, scale-up of compound synthesis, and freedom to operate. Assuming successful preclinical development, Curis expects to select a lead clinical candidate during the first half of 2007 and to file an Investigational New Drug, or IND, application by the end of 2007.

Curis expects that the cost efficiencies of its Chinese operations will allow continued development of these cancer programs as well as additional drug programs. These additional drug programs may be developed internally or acquired through in-licensing activities.

About Curis' Operations in China

Curis' operations in China will be located in Zhangjiang Hi-tech Park, Pudong, Shanghai. Programs at Curis Shanghai will initially be focused on the development of small molecule drugs that target multiple validated cancer pathways, with potential future focus areas in neurology and dermatology. The subsidiary will primarily perform medicinal chemistry services. Overall scientific leadership, program management and in vivo animal work will continue to be conducted by Curis in the U.S., where the Company has an established infrastructure.

In the near-term, these operations will provide oversight to the medicinal chemistry services that are being conducted at Shanghai ChemPartner. In the future, Curis will evaluate whether it would be more advantageous to hire its own scientists and administrative staff for the purposes of performing the medicinal chemistry services that are currently provided by Shanghai ChemPartner.

Curis has engaged approximately 20 chemists through Shanghai ChemPartner, who are working to advance its multi-targeted pathway inhibitor cancer programs. Curis has also achieved in vitro efficacy results in a preclinical cancer model for one of its new cancer drug candidates. Medicinal chemistry efforts for this compound were provided by Shanghai ChemPartner. Curis believes that this early success is a positive indicator for the viability of its new cancer programs and its strategy of pursuing medicinal chemistry efforts in China.

Personnel from Curis' U.S. operations and its Chinese subsidiary, including contracted chemists at Shanghai ChemPartner, will comprise a nearly "24/7" drug discovery and development operation, which Curis believes may result in enhanced capacity, greater productivity and new cost efficiencies. Curis anticipates that its chemistry costs will be reduced by 65%-75% compared to outsourcing chemistry with traditional western chemistry providers. The Company also believes that this cost efficiency should allow it to progress more drug programs than it could under western drug development economics.

By enabling Curis to increase internal development of compounds, implementation of this model is intended to increase the likelihood that Curis could expeditiously advance a drug candidate into further preclinical and, ultimately, clinical development.

Upcoming Goals and Objectives

Curis' near-term goal is to announce in vivo efficacy for at least one or two of its new cancer drug candidates. Curis anticipates achieving this objective in the second half of 2006. If this near-term goal is achieved, Curis could expect to select a lead clinical candidate during the first half of 2007 and to file an IND application by the end of 2007. In addition, Curis expects to either internally develop or in-license at least one additional drug program in the next six to twelve months.

Curis intends to continue to leverage important professional relationships in China in its efforts to achieve its key goals. Many of Curis' U.S.-based scientists were born and raised in China, and have maintained relationships with their peers in the country. These relationships were instrumental in the successful formation of Curis Shanghai and are expected to provide continued benefits in maintained continuity and communication between Curis, its subsidiary, and Shanghai ChemPartner.

Curis is also seeking to achieve a number of important upcoming development objectives with respect to its Hedgehog-based programs that are under collaboration with Genentech, Wyeth and Procter & Gamble. These objectives include the following:

-- Curis expects that, during the second half of 2006, Genentech
will file an IND application for solid tumor indications under
the Hedgehog antagonist relationship. The IND filing would
result in a cash payment to Curis.

-- Curis and Wyeth are currently testing Hedgehog agonist
compounds in various toxicology and efficacy models. If these
tests are satisfactorily completed, Curis is hopeful that
Wyeth will select a lead clinical development candidate during
either the second half of 2006 or the first half of 2007.
Curis is also continuing to screen for additional backup
Hedgehog agonist compound classes.

-- Curis is hopeful that, during the first half of 2007, Procter
& Gamble may achieve the second preclinical development
objective under the topically-applied Hedgehog agonist hair
growth partnership. This development objective is met upon the
selection by P&G of a lead clinical candidate for hair growth
and results in a $1.8 million cash payment to Curis.

Financial Guidance

Curis currently estimates that Curis Shanghai's 2007 expenses will approximate $1.5-$1.6 million, approximately all of which are research-related expenses to support approximately 20 chemists. Curis believes that existing cash, cash equivalents, marketable securities and investments, together with contractually defined cash payments that it expects to receive under its collaborations with Genentech and Wyeth, will be sufficient to support its current operating plans into 2008. The Company expects to end 2006 with cash, cash equivalents, marketable securities and investments of between $30 million and $31 million, and will seek to continue to carefully manage its cash consumption. This year-end projection does not include any cash payments the Company could receive from its collaborators assuming the achievement of specified development objectives.
http://phx.corporate-ir.net/phoenix.zhtml?c=123198&p=irol-newsArticle&t=Regular&id=904140&

Curis, Inc. Augments Scientific Advisory Board with Leaders in Cancer Research and Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 18, 2006--Curis, Inc., (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, announced the addition of three new members to its Scientific Advisory Board:

-- Stuart A. Aaronson, M.D., Chairman, Department of Oncological
Sciences at The Mount Sinai Medical Center in New York City,
and the Jane B. and Jack R. Aron Professor of Neoplastic
Diseases

-- Kenneth J. Pienta, M.D., Professor, Internal Medicine and
Urology; Director of the Urologic Oncology program at the
University of Michigan Comprehensive Cancer Center; Chair,
Translational Medicine Committee of the Southwest Oncology
Group (SWOG)

-- George F. Vande Woude, Ph.D., Director, Van Andel Research
Institute; formerly with the National Cancer Institute

These advisors bring a broad understanding of oncology to Curis, as well as deep experience advising biotechnology and pharmaceutical companies in various stages of growth. Curis has determined that a majority of its new scientific advisors will possess strong backgrounds in oncology since a majority of Curis' drug development programs, including its new proprietary drug programs, are for oncology indications. Curis' new advisors join Joseph M. Davie, M.D., Ph.D., and Roeland Nusse, Ph.D. on Curis' Scientific Advisory Board.

"We are extremely pleased to have such a distinguished group of advisors helping to guide Curis' drug development programs," said Jospeh M. Davie, M.D., Ph.D., Chairman of Curis' Scientific Advisory Board. "We anticipate that these advisors will be important to Curis and its scientific team as we continue the development of our new proprietary oncology drug programs. The new programs include several classes of proprietary small molecule drug candidates, each of which is designed to target multiple distinct molecular pathways."

"We have reshaped Curis' Scientific Advisory Board to include broad research and clinical development understanding," said Curis President and CEO, Daniel R. Passeri. "We're confident that the involvement of our new Scientific Advisory Board members will provide Curis with important oversight and guidance as we continue to implement our strategy of focusing on later stage preclinical and, we expect, ultimately, on clinical, drug development programs."

About the Scientific Advisory Board Members

Joseph M. Davie, M.D., Ph.D., Chairman

Dr. Davie has served on the Curis board since July 2003. From 1993 to 2000, he was the Senior Vice President of Research at Biogen, Inc., now Biogen Idec. Prior to joining Biogen, Dr. Davie held several senior positions at G.D. Searle and Co., including Senior Vice President of Science and Technology and President of Research and Development. Dr. Davie serves on the boards of several public and private biotechnology companies. He received his M.D. from the Washington University School of Medicine and his Ph.D. from Indiana University.

Stuart A. Aaronson, M.D.

Dr. Aaronson is currently the Chairman for the Department of Oncological Sciences at The Mount Sinai Medical Center in New York City, and the Jane B. and Jack R. Aron Professor of Neoplastic Diseases at the school. He has been recognized for his accomplishments throughout the years with numerous awards and medals, including the Distinguished Service Medal Award from the U.S. Public Health Service, the Rhoads Memorial Award from the American Association of Cancer Research and the Paul Erhlich Prize from Germany.

Dr. Aaronson is the author of more than 530 publications, an inventor on more than 50 patents and serves on numerous editorial boards and scientific advisory committees.

Roeland Nusse, Ph.D

Dr. Nusse is Professor of Developmental Biology at Stanford University Medical School. He joined Stanford in 1990 as Associate Professor of Developmental Biology and was at the same time appointed as a Howard Hughes Medical Institute Investigator. He became Full Professor in 1994 and served as Chair of the Department of Developmental Biology from 1999-2003. During his career, Dr. Nusse has made several of the most important discoveries regarding Wnt signaling, now recognized as a key player in various cancers, including human colon cancer. Dr. Nusse was elected to the Royal Dutch Academy of Science in 1997 and the American Academy of Arts and Sciences in 2001.

Kenneth J. Pienta, M.D.

Dr. Pienta is Professor of Internal Medicine and Urology and the Director of the Urologic Oncology program at the University of Michigan Comprehensive Cancer Center. He is also the chair of the Translational Medicine Committee of the Southwest Oncology Group (SWOG). Dr. Pienta has international expertise in the development of novel chemotherapeutic programs for prostate cancer and is the principal investigator on The University of Michigan's SPORE (Specialized Program of Research Excellence) in prostate cancer awarded from the National Cancer Institute. In 2003, Dr. Pienta received the American Cancer Society Clinical Research Professor Award in recognition of his achievements in translational research. He is the author of more than 200 peer-reviewed articles and 50 book chapters.

Currently, Dr. Pienta is involved in research to understand the process of prostate cancer metastasis to bone as well as developing new therapies for prostate cancer.

George F. Vande Woude, Ph.D.

Dr. George F. Vande Woude is the Director of the Van Andel Research Institute in Grand Rapids, Michigan. He spent more than thirty years at the National Cancer Institute in a variety of roles, most notably that of Special Advisor to the Director of the National Cancer Institute and Director of the Division of Sciences (1998-1999), where he reorganized the intramural basic sciences.

Dr. Vande Woude is the author of over 250 scientific research articles and over 60 articles in books or monographs. He has served as Editor of Journal of Virology and as an Editorial Board Member of Cell, Cancer Research, and Journal of Virology and is currently as an Editorial Board Member of Oncogene, Molecular Imaging, Cancer Letters, Cell Cycle and Molecular Cancer Research. Dr. Vande Woude was Founding Editor of Cell Growth and Differentiation and, since 1989, has been Co-editor (with George Klein) of Advances in Cancer Research.

Through the course of his 45-year scientific career, Dr. Vande Woude has mentored more than 70 postdoctoral fellows, students, and visiting scientists. His laboratory has published over 300 research articles that have been referenced on more than 8500 occasions.
http://phx.corporate-ir.net/phoenix.zhtml?c=123198&p=irol-newsArticle&t=Regular&id=906170&

New Presentation: and updated curis site.


http://www.curis.com/Curis_Presentation_06September12.pdf

Curis to Present at Noble Financial's Small Cap Conference and Micro Cap Symposium, Titled 'OnTrack 2006'

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 21, 2006--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurology and dermatology disease indications, today announced that the company will be presenting at Noble Financial's Small Cap Conference and Micro Cap Symposium, titled OnTrack 2006, which is being held from September 26 through September 28. The company's presentation will take place on Wednesday, September 27th, in the Bristol Room at the Lowe's Motor Speedway/Ballantyne Spa and Golf resort in Charlotte, North Carolina.

Daniel Passeri, Curis's President and CEO, will provide an overview of the status of the company's business and collaborations from 2:15 to 2:40 p.m. There will also be a corresponding webcast of the presentation, which can be accessed by visiting: http://www.ontrack06.com/webcast.html

The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will also be available on the Investor Relations section of the Curis website at www.curis.com.

Very Good Presentation. Worth listenting to

Also newest CURIS pdf
http://www.pathway2curis.com/pdf/Curis_Presentation_06.pdf